Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM09 SCIT in HDM-Allergic Rhinitis and Asthma
NCT04435990Phase 3Recruiting
- Sponsor
- Inmunotek
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Split/Subunit Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of Clustoid MM09 in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma, sponsored by Inmunotek. Started Oct 2020; status: recruiting.
02
Drugs
Clustoid MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT04435990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435990.